Kineta announced Thursday that it is laying off 64% of its workforce, or seven employees — including its CEO Shawn Iadonato — as it undergoes a restructuring process.
— Seattle venture capital firm Madrona Venture Group announced it added three new venture partners: Loren Alhadeff, Mark Nelson, and Ted Kummert. Alhadeff, formerly the COO of DocuSign, has more… Read More
Seattle biotech company Kineta completed its merger with Yumanity Therapeutics, a move that makes Kineta a public company. The combined company began trading Monday on the Nasdaq under the symbol… Read More
— Maggie Brady, previously a human resources group leader at fintech company Fiserv, is now head of people at trucking marketplace Convoy. Brady previously also led human resources teams at… Read More
Seattle biotech company Kineta is going public through a merger with Yumanity Therapeutics, a neurosciences company based in Boston. Yumanity will also sell part of its pipeline to Johnson &… Read More
Proteins, algorithms and apps — oh my! Health innovators across the Pacific Northwest continue to embrace technologies that go well beyond traditional drugs. The finalists for the Health Innovation of… Read More
Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an agreement with drug giant Pfizer that includes $15 million in… Read More
As the U.S. opioid epidemic rages on, the need for effective alternative pain medications is only becoming more acute. Seattle-based biotechnology company Kineta has been working on a non-opioid pain… Read More
If you didn’t know snails could be venomous, you’re not alone. But it turns out some are, and a recent study found that one species in particular has a venom… Read More
Seattle-based biotech startup Kineta announced today that it has received an undisclosed amount of funding to expand research that could potentially combat the Zika virus. The funding comes from the National Institute… Read More
Seattle-based biotech startup Kineta today announced that it won a $7.2 million award to develop an antiviral drug therapy for treating Lassa haemorrhagic fever. The money comes from The Wellcome… Read More
Seattle-based biotech startup Kineta today announced that it won a $4 million federal contract from the National Institute of Allergy and Infectious Diseases (NIAID) to develop new immunotherapies against respiratory viral… Read More
A consortium that includes Seattle-based biotech company Kineta, UW Medicine, and the University of Washington’s CoMotion group is seeking to raise an additional $7 million in a Series C financing round, according… Read More
Kineta, a Seattle-based biotech startup, has raised an investment round worth almost $1.6 million from existing investors in the company. The investment will be used to fund continued development of the… Read More
The University of Washington, University of Texas Medical Branch and Kineta — a Seattle biotechnology upstart — have received an $8.1 million grant from the National Institute of Allergy and Infectious… Read More